{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:07:52Z","timestamp":1771286872870,"version":"3.50.1"},"reference-count":51,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Therapie des Urothelkarzinoms befindet sich in einem rasanten Wandel. Sowohl f\u00fcr das nicht muskelinvasive Urothelkarzinom (NMIBC) als auch das muskelinvasive Urothelkarzinom (MIBC) werden moderne Substanzen in verschiedenen Therapiekonzepten zur Senkung der Rezidiv- und Progressionsrisiken als auch zur Steigerung der Blasenerhaltsraten (insbesondere beim MIBC bzw. beim BCG-refrakt\u00e4ren high\/very high risk NMIBC) getestet. Hierbei spielen insbesondere Antik\u00f6rper-Wirkstoff-Konjugate (ADC) wie Enfortumab Vedotin und neue Immuntherapien eine zentrale Rolle. Kontrovers bleibt allerdings nach welchen Ma\u00dfgaben Patienten mit NMIBC mittels Fr\u00fchzystektomie bzw. Patienten mit MIBC blasenerhaltend therapiert werden sollten bzw. k\u00f6nnten. Die vorliegende Arbeit beleuchtet die derzeit geltenden Therapiestandards in diesem kontroversen Kontext und geht dabei auf potenzielle histopathologische sowie molekulare Stratifizierungshilfen ein, um k\u00fcnftig eine gezieltere Patientenselektion zu erm\u00f6glichen und lenken zu k\u00f6nnen.<\/jats:p>","DOI":"10.1055\/a-2714-2306","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T23:05:20Z","timestamp":1761260720000},"page":"52-59","source":"Crossref","is-referenced-by-count":0,"title":["Pathologische Risikostratifizierung des nicht muskelinvasiven und muskelinvasiven Urothelkarzinoms zur optimalen Therapieentscheidung"],"prefix":"10.1055","volume":"57","author":[{"given":"Fabienne","family":"Lange","sequence":"first","affiliation":[{"name":"Institute of Pathology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine Therese","family":"Gaisa","sequence":"first","affiliation":[{"name":"Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Ulm, Ulm, Germany"},{"name":"Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Aachen, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bolenz","sequence":"first","affiliation":[{"name":"Urology, Universit\u00e4tsklinikum Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Kl\u00fcmper","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Urologie und Kinderurologie, Universit\u00e4tsklinikum Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Roghmann","sequence":"first","affiliation":[{"name":"Urology, Ruhr University Bochum, Herne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Eckstein","sequence":"first","affiliation":[{"name":"Institute of Pathology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel","volume":"79","author":"RJ Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"M Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","article-title":"Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?","volume":"69","author":"RJ Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"ref5","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"M Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.eururo.2004.05.003","article-title":"One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?","volume":"46","author":"JR Oddens","year":"2004","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"E34","DOI":"10.1111\/bju.12340","article-title":"Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC) \u2013 avoidance, recognition, management and consent","volume":"113","author":"MH Elmamoun","year":"2014","journal-title":"BJU Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"JL Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","article-title":"Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer \u2013 The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg\/40ml, 30mg\/40ml, 40mg\/40ml","volume":"45","author":"M Kuroda","year":"2004","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1464-410x.1989.tb05159.x","article-title":"Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times","volume":"63","author":"AA Giesbers","year":"1989","journal-title":"Br J Urol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"RJ Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"DL Lamm","year":"2000","journal-title":"J Urol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/s0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"DL Lamm","year":"1992","journal-title":"J Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011935.pub2","article-title":"Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"S Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1023\/a:1019507104741","article-title":"Intravesical treatment of severe bacillus Calmette-Guerin cystitis","volume":"33","author":"J Palou","year":"2001","journal-title":"Int Urol Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"AV Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"BW van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2559.2011.03989.x","article-title":"Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series","volume":"59","author":"S Bertz","year":"2011","journal-title":"Histopathology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/bju.16298","article-title":"A novel grading approach predicts worse outcomes in stage pT1 non-muscle-invasive bladder cancer","volume":"134","author":"M Haas","year":"2024","journal-title":"BJU Int"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"JP Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0022-5347(05)66440-3","article-title":"Cystectomy for bladder cancer: a contemporary series","volume":"165","author":"G Dalbagni","year":"2001","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urolonc.2009.03.021","article-title":"Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer","volume":"29","author":"MP Porter","year":"2011","journal-title":"Urol Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines","volume":"87","author":"AG van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bju.15434","article-title":"Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration","volume":"128","author":"P Ravi","year":"2021","journal-title":"BJU Int"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1097\/CCM.0000000000005337","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"International Collaboration of Trialists;\u00a0Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical  Studies Group);\u00a0European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/cncr.30907","article-title":"Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology","volume":"123","author":"MW Vetterlein","year":"2017","journal-title":"Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"T Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines(R) Insights: Bladder Cancer, Version 3.2024","volume":"22","author":"TW Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bju.14636","article-title":"Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis","volume":"124","author":"M Mossanen","year":"2019","journal-title":"BJU Int"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ejso.2020.09.040","article-title":"The comprehensive complication index is associated with a significant increase in complication severity between 30 and 90 days after radical cystectomy for bladder cancer","volume":"47","author":"M Haas","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104137","article-title":"Bladder-sparing treatment for muscle-invasive bladder carcinoma using immune checkpoint inhibitors","volume":"191","author":"C Xu","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic","volume":"35","author":"GS Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer","volume":"41","author":"M Swinton","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"AR Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"J Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/SUO Guideline (2017; Amended 2020, 2024)","volume":"212","author":"J Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"S 6","key":"ref38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2023.41.6_suppl.447","article-title":"Co-primary endpoint analysis of HCRN GU 16\u2013257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC)","volume":"41","author":"MD Galsky","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)","volume":"43","author":"DM Geynisman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"S 5","key":"ref40","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/JCO.2025.43.5_suppl.815","article-title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)","volume":"43","author":"P Ghatalia","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"T Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"T Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"S 15","key":"ref43","doi-asserted-by":"crossref","first-page":"TPS4587","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4587","article-title":"KEYNOTE-B15\/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC)","volume":"39","author":"CJ Hoimes","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"ref44","volume-title":"Urinary and male genital tumours. WHO classification of tumours series","author":"WHO Classification of Tumours Editorial Board","year":"2022","edition":"5"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.euo.2023.07.011","article-title":"Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes","volume":"7","author":"M Eckstein","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.urolonc.2012.04.009","article-title":"Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital","volume":"31","author":"RB Shah","year":"2013","journal-title":"Urol Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"V Bahlinger","year":"2024","journal-title":"Histopathology"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"27","author":"CE Chu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"PM Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance","volume":"29","author":"N Klumper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","volume":"42","author":"N Klumper","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"F Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","article-title":"Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype","volume":"80","author":"U Zinnall","year":"2018","journal-title":"Hum Pathol"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2714-2306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:40:44Z","timestamp":1771285244000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2714-2306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":51,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2714-2306","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}